Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'zolmitriptan' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 87 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Gruffyd-Jones, K; Kies, B; Middleton, A; Mulder, LJMM; Rosjo, O; Millson, DS
      Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double-blind, international study

      EUROPEAN JOURNAL OF NEUROLOGY
    2. Eadie, MJ
      Clinically significant drug interactions with agents specific for migraineattacks

      CNS DRUGS
    3. Pascual, J; Munoz, R; Leira, R
      An open preference study with sumatriptan 50 mg and zolmitriptan 2.5 mg in100 migraine patients

      CEPHALALGIA
    4. Meckling, SK; Becker, WJ; Rose, MS; Dalby, JT
      Sumatriptan responsiveness and clinical, psychiatric and psychologic features in migraine patients

      CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
    5. Gawel, MJ; Worthington, I; Maggisano, A
      Progress in clinical neurosciences - A systematic review of the use of triptans in acute migraine

      CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
    6. Jhee, SS; Shiovitz, T; Crawford, AW; Cutler, NR
      Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents -A comparative review

      CLINICAL PHARMACOKINETICS
    7. Adelman, JU; Adelman, RD
      Current options for the prevention and treatment of migraine

      CLINICAL THERAPEUTICS
    8. Solomon, S; Frishberg, B; Hu, XH; Markson, L; Berger, M
      Migraine treatment outcomes with rizatriptan in triptan-naive patients: A naturalistic study

      CLINICAL THERAPEUTICS
    9. Fuseau, E; Petricoul, O; Sabin, A; Pereira, A; O'Quinn, S; Thein, S; Leibowitz, M; Purdon, H; McNeal, S; Salonen, R; Metz, A
      Effect of encapsulation on absorption of sumatriptan tablets: Data from healthy volunteers and patients during a migraine

      CLINICAL THERAPEUTICS
    10. Jandu, KS; Barrett, V; Brockwell, M; Cambridge, D; Farrant, DR; Foster, C; Giles, H; Glen, RC; Hill, AP; Hobbs, H; Honey, A; Martin, GR; Salmon, J; Smith, D; Woollard, P; Selwood, DL
      Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and apotent inhibitor of electrically induced plasma extravasation

      JOURNAL OF MEDICINAL CHEMISTRY
    11. Lipton, RB; Pascual, J; Goadsby, PJ; Massiou, H; McCarroll, KA; Vandormael, K; Jiang, KH; Lines, CR
      Effect of rizatriptan and other triptans on the nausea symptom of migraine: A post hoc analysis

      HEADACHE
    12. Sheftell, FD; Fox, AW; Weeks, RE; Tepper, SJ
      Differentiating the efficacy of 5-HT1B/1D agonists

      HEADACHE
    13. Pascual, J; Falk, R; Docekal, R; Prusinski, A; Jelencsik, J; Cabarrocas, X; Segarra, X; Luria, X; Ferrer, P
      Tolerability and efficacy of almotriptan in the long-term treatment of migraine

      EUROPEAN NEUROLOGY
    14. Johnson, DE; Rollema, H; Schmidt, AW; McHarg, AD
      Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain

      EUROPEAN JOURNAL OF PHARMACOLOGY
    15. Bhalla, P; Sharma, HS; Ma, XQ; Wurch, T; Pauwels, PJ; Saxena, PR
      Molecular cloning, pharmacological properties and tissue distribution of the porcine 5-HT1B receptor

      BRITISH JOURNAL OF PHARMACOLOGY
    16. de Almeida, RMM; Nikulina, EM; Faccidomo, S; Fish, EW; Miczek, KA
      Zolmitriptan - a 5-HT1B/D agonist, alcohol, and aggression in mice

      PSYCHOPHARMACOLOGY
    17. Goadsby, PJ; Peatfield, R
      Zolmitriptan in the acute treatment of migraine: An overview

      REVIEWS IN CONTEMPORARY PHARMACOTHERAPY
    18. Edmeads, J; Johnson, FN
      The adverse event and tolerability profile of zolmitriptan

      REVIEWS IN CONTEMPORARY PHARMACOTHERAPY
    19. Evers, S; Gendolla, A
      Acute treatment of menstrual migraine with zolmitriptan - Results of a post-marketing trial

      NERVENHEILKUNDE
    20. Mick, G
      Physiopathology of the migraine attack and the mechanisms of action of antimigraine agents: recent findings in animals

      PATHOLOGIE BIOLOGIE
    21. Pascual, J; Vega, P; Diener, HC; Allen, C; Vrijens, F; Patel, K
      Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine

      CEPHALALGIA
    22. Geraud, G; Olesen, J; Pfaffenrath, V; Tfelt-Hansen, P; Zupping, R; Diener, HC; Sweet, R
      Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design

      CEPHALALGIA
    23. Moeller, FG; Bjork, JM; Dougherty, DM; Van de Kar, LD; Marsh, DM; Swann, AC
      Low dose zolmitriptan as a 5-HT neuroendocrine challenge agent in humans

      PSYCHONEUROENDOCRINOLOGY
    24. de Tommaso, M; Guido, M; Libro, G; Sciruicchio, V; Puca, F
      Zolmitriptan reverses blink reflex changes induced during the migraine attack in humans

      NEUROSCIENCE LETTERS
    25. Lipton, RB; Stewart, AF; Stone, FM; Lainez, MJA; Sawyer, JPC
      Stratified cave vs step care strategies for migraine - The disability in strategies of care (DISC) study: A randomized trial

      JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    26. Deleu, D; Hanssens, Y
      Current and emerging second-generation triptans in acute migraine therapy:A comparative review

      JOURNAL OF CLINICAL PHARMACOLOGY
    27. Sturzenegger, M; Daems, K; Billeter, M
      Zolmitriptan in the treatment of migraine attacks - the ARES study

      SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT
    28. Boers, PM; Donaldson, C; Zagami, AS; Lambert, GA
      5-HT1A and 5-HT1B/1D receptors are involved in the modulation of the trigeminovascular system of the cat: a microiontophoretic study

      NEUROPHARMACOLOGY
    29. Saper, JR
      The use of rizatriptan in the treatment of acute, multiple migraine attacks

      NEUROLOGY
    30. Bahra, A; Gawel, MJ; Hardebo, JE; Millson, D; Breen, SA; Goadsby, PJ
      Oral zolmitriptan is effective in the acute treatment of cluster headache

      NEUROLOGY
    31. Patrick, DL; Hurst, BC; Hughes, J
      Further development and testing of the migraine-specific quality of life (MSQOL) measure

      HEADACHE
    32. Mathew, NT; Kailasam, J; Gentry, P; Chernyshev, O
      Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: A comparative open trial

      HEADACHE
    33. Sheftell, F; O'Quinn, S; Watson, C; Pait, D; Winter, P
      Low migraine headache recurrence with naratriptan: Clinical parameters related to recurrence

      HEADACHE
    34. Gallagher, RM; Dennish, G; Spierings, ELH; Chitra, R
      A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine

      HEADACHE
    35. Vijayan, N; Peacock, JH
      Spinal cord infarction during use of zolmitriptan: A case report

      HEADACHE
    36. Le Grand, B; Panissie, A; Perez, M; Pauwels, PJ; John, GW
      Zolmitriptan stimulates a Ca2+-dependent K+ current in C6 glioma cells stably expressing recombinant human 5-HT1B receptors

      EUROPEAN JOURNAL OF PHARMACOLOGY
    37. Bhalla, P; Sharma, HS; Wurch, T; Pauwels, PJ; Saxena, PR
      Molecular cloning, sequence analysis and pharmacological properties of theporcine 5-HT1D receptor

      BRITISH JOURNAL OF PHARMACOLOGY
    38. Boshuisen, ML; den Boer, JA
      Zolmitriptan (a 5-HT1B/1D receptor agonist with central action) does not increase symptoms in obsessive compulsive disorder

      PSYCHOPHARMACOLOGY
    39. Diener, HC; Limmroth, V
      Acute management of migraine: triptans and beyond

      CURRENT OPINION IN NEUROLOGY
    40. Dulli, DA
      Naratriptan: An alternative for migraine

      ANNALS OF PHARMACOTHERAPY
    41. Diener, HC; Kaube, H; Limmroth, V
      Antimigraine drugs

      JOURNAL OF NEUROLOGY
    42. Diener, HC; Dowson, AJ; Ferrari, M; Nappi, G; Tfelt-Hansen, P
      Unbalanced randomization influences placebo response: scientific versus ethical issues around the use of placebo in migraine trials

      CEPHALALGIA
    43. Jhee, SS; Salazar, DE; Ford, NF; Fulmor, IE; Sramek, JJ; Cutler, NR
      A double-blind, randomized, crossover assessment of blood pressure following administration of avitriptan, sumatriptan, or placebo to patients with mild to moderate hypertension

      CEPHALALGIA
    44. Hughes, AM; Dixon, R; Dane, A; Kemp, J; Cummings, L; Yates, RA
      Effects of zolmitriptan (Zomig (TM)) on central serotonergic neurotransmission as assessed by active oddball auditory event-related potentials in volunteers without migraine

      CEPHALALGIA
    45. Roon, KI; Sandor, PS; Schoonman, GG; Lamers, FPL; Schoenen, J; Ferrari, MD; van Dijk, JG
      Auditory evoked potentials in the assessment of central nervous system effects of antimigraine drugs

      CEPHALALGIA
    46. Dixon, R
      Measuring event-related potentials

      CEPHALALGIA
    47. Goadsby, PJ
      The scientific basis of medication choice in symptomatic migraine treatment

      CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
    48. Storer, RJ; Goadsby, PJ
      Trigeminovascular nociceptive transmission involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors

      NEUROSCIENCE
    49. Deleu, D; Hanssens, Y
      Profiles of 5-HT1B/1D agonists in acute migraine with special reference tosecond generation agents

      ACTA NEUROLOGICA BELGICA
    50. Tepper, SJ; Donnan, GA; Dowson, AJ; Bomhof, MAM; Elkind, A; Meloche, J; Fletcher, PE; Millson, DS
      A long-term study to maximise migraine relief with zolmitriptan

      CURRENT MEDICAL RESEARCH AND OPINION
    51. Tuchman, M; Edvinsson, L; Geraud, G; Korczyn, A; Mauskop, A; Pfaffenrath, V
      Zolmitriptan provides consistent migraine relief when used in the long term

      CURRENT MEDICAL RESEARCH AND OPINION
    52. Mauskop, A; Farkkila, M; Hering-Hanit, R; Rapoport, A; Warner, J
      Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache

      CURRENT MEDICAL RESEARCH AND OPINION
    53. Weitzel, KW; Thomas, ML; Small, RE; Goode, JVR
      Migraine: A comprehensive review of new treatment options

      PHARMACOTHERAPY
    54. Becker, WJ
      Use of oral contraceptives in patients with migraine

      NEUROLOGY
    55. Mathew, NT; Asgharnejad, M; Peykamian, M; Laurenza, A
      Naratriptan is effective and well tolerated in the acute treatment of migraine - Reply

      NEUROLOGY
    56. Roon, KI; MaassenVanDenBrink, A; Ferrari, MD; Saxena, PR
      Bovine isolated middle cerebral artery contractions to antimigraine drugs

      NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
    57. Kemp, DM; George, SE; Bungay, PJ; Naylor, LH
      Partial agonism at serotonin 5-HT1B and dopamine D-2L receptors using a luciferase reporter gene assay

      EUROPEAN JOURNAL OF PHARMACOLOGY
    58. Nilsson, T; Longmore, J; Shaw, D; Pantev, E; Bard, JA; Branchek, T; Edvinsson, L
      Characterisation of 5-HT receptors in human coronary arteries by molecularand pharmacological techniques

      EUROPEAN JOURNAL OF PHARMACOLOGY
    59. Spencer, CM; Gunasekara, NS; Hills, C
      Zolmitriptan - A review of its use in migraine

      DRUGS

    60. Zolmitriptan - New product similar to sumatriptan

      CANADIAN FAMILY PHYSICIAN
    61. Whale, R; Bhagwagar, Z; Cowen, PJ
      Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1Dreceptors?

      PSYCHOPHARMACOLOGY
    62. DAHLOF C; DIENER HC; GOADSBY PJ; MASSIOU H; OLESEN J; SCHOENEN J; WILKINSON M; SWEET RM; KLEIN KB
      ZOLMITRIPTAN, A 5-HT1B 1D RECEPTOR AGONIST FOR THE ACUTE ORAL TREATMENT OF MIGRAINE - A MULTICENTER, DOSE-RANGE FINDING STUDY/

      European journal of neurology

    63. CURRENT TREATMENT STRATEGIES FOR MIGRAINE DISORDER

      American journal of managed care
    64. SMITH DA; CLEARY EW; WATKINS S; HUFFMAN CS; POLVINO WJ
      ZOLMITRIPTAN (311C90) DOES NOT INTERACT WITH FLUOXETINE IN HEALTHY-VOLUNTEERS

      International journal of clinical pharmacology and therapeutics
    65. DIXON R; HUGHES AM; NAIRN K; SELLERS M; KEMP JV; YATES RA
      EFFECTS OF THE ANTIMIGRAINE COMPOUND ZOLMITRIPTAN (ZOMIG) ON PSYCHOMOTOR PERFORMANCE ALONE AND IN COMBINATION WITH DIAZEPAM IN HEALTHY-VOLUNTEERS

      Cephalalgia
    66. SEABER EJ; PECK RW; SMITH DA; ALLANSON J; HEFTING NR; VANLIER JJ; SOLLIE FAE; WEMER J; JONKMAN JHG
      THE ABSOLUTE BIOAVAILABILITY AND EFFECT OF FOOD ON THE PHARMACOKINETICS OF ZOLMITRIPTAN IN HEALTHY-VOLUNTEERS

      British journal of clinical pharmacology
    67. ADELMAN JU; BAUMEL B; CADY RK; BAKER CC; COUCH JR; DALESSIO DJ; DIAMOND S; ELKIND AH; FOSTER CA; GOLDSTEIN J; KATZ DA; KIRCHNER JR; KLAPPER JA; KUDROW DB; KUNKEL R; LANDY SH; LICHT JM; LINDER SL; LODER E; MARKLEY HG; MATHEW NT; MEYER JS; NETT R; PACKARD RC; PERSE T; PETERS KS; RAMADAN NM; RAPOPORT AM; ROSING HS; SADOWSKY C; SAPER JR; SHARFMAN MI; SILBERSTEIN SD; SINGER RP; SMITH R; SOLOMON G; SOLOMON S; STARK SR; SWANSON JW; TAYLOR FR; TEPPER SJ; TUCHMAN MM; VIJAYAN N; WALKER J; WARD T; WARNER JS; WENDT JK; WINNER P; BERAN P; BLACK A; DONNAN G; HERKES G; LORD G; ZAGAMI A; BAUMHACKL U; BROUSSALIS T; KLINGLER D; LADURNER G; JACQUY J; LOUIS P; SCHOENEN J; GAWEL MJ; HANSEN PE; JENSEN K; PEDERSEN KK; KORSGAARD A; LADEMANN A; OLESEN J; SIMONSEN N; SORENSEN PS; JENSEN TS; TFELTHANSEN P; KAASIK AE; ZUPPING R; FARKKILA M; HAANPAA M; HAVANKA H; HEDMAN C; ILMAVIRTA M; KINNUNEN E; LIUKKONEN J; PARTINEN M; RAUTAKORPI I; REUNANEN M; SAKO E; SEPPA JM; BAREGE M; CHAZOT G; COLOMBANI JP; DUJARDIN M; FABRE N; GIACOMINO A; GERAUD G; HENRY P; JOGEIX; LAPORTE A; LICHTBLAU; MASSIOU H; MAZINGUEDESAILLY; MIHOUT B; PETIT H; VEYRIE M; VILAREM H; WILMANN JF; BECKMANNREINHOLDT A; DIENER HC; EVERS S; GOBEL H; KLEPEL H; KUHL W; LANGOHR HD; NEU I; PAULUS W; PEIKERT A; PFAFFENRATH V; SCHOLZ E; STRAUBE A; WITTE OW; HARMOUSI S; KARAGEORGIOU C; MILONAS I; GIACOVAZZO M; NAPPI G; TERBERG JWM; SANDERS EACM; VANDERZWAN JL; EDLAND A; ENGELSEN B; GRONNING M; HALDORSEN T; HODNEBO A; LARSEN JP; DORNZAL T; PRUSINSKI A; SZCZUDLIK A; NAYA MG; GRANELL AN; LAINEZ JM; LEIRA R; LIANO H; PASCUAL J; BOIVIE J; DAHLOF C; EDVINSSON L; HARDEBO JE; NILSSON H; WALDENLIND E; ISLER HR; CRAWFORD P; DOWSON AJ; FINDLEY L; GROSS M; HAWKES CH; JESTICO J; ROLAN P; STEINER TJ; WILKINSON M; WAGNER G
      THE LONG-TERM TOLERABILITY AND EFFICACY OF ORAL ZOLMITRIPTAN (ZOMIG, 311C90) IN THE ACUTE TREATMENT OF MIGRAINE - AN INTERNATIONAL STUDY

      Headache
    68. HOSKIN KL; GOADSBY PJ
      COMPARISON OF MORE AND LESS LIPOPHILIC SEROTONIN (5HT(1B 1D)) AGONISTS IN A MODEL OF TRIGEMINOVASCULAR NOCICEPTION IN CAT/

      Experimental neurology
    69. Cumberbatch, MJ; Hill, RG; Hargreaves, RJ
      The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats

      EUROPEAN JOURNAL OF PHARMACOLOGY
    70. MacLennan, SJ; Cambridge, D; Whiting, MV; Marston, C; Martin, GR
      Cranial vascular effects of zolmitriptan, a centrally active 5-HT1B/1D receptor partial agonist for the acute treatment of migraine

      EUROPEAN JOURNAL OF PHARMACOLOGY
    71. PAGNIEZ F; VALENTIN JP; VIEU S; COLPAERT FC; JOHN GW
      PHARMACOLOGICAL ANALYSIS OF THE HEMODYNAMIC-EFFECTS OF 5-HT1B D RECEPTOR AGONISTS IN THE NORMOTENSIVE RAT/

      British Journal of Pharmacology
    72. Mercer, AJ; Lamb, RJ; Rolan, PE; Gibbens, M; Posner, J
      Lack of an effect of zolmitriptan (Zomig, 311C90) on psychometric task performance: results of a placebo-controlled study in healthy volunteers

      PSYCHOPHARMACOLOGY
    73. GILLOTIN C; BAGNIS C; MAMET JP; PECK RW; DERAY G
      NO NEED TO ADJUST THE DOSE OF 311C90 (ZOLMITRIPTAN), A NOVEL ANTIMIGRAINE TREATMENT, IN PATIENTS WITH RENAL-FAILURE NOT REQUIRING DIALYSIS

      International journal of clinical pharmacology and therapeutics
    74. PROIETTICECCHINI A; AFRA J; SCHOENEN J
      INTENSITY DEPENDENCE OF THE CORTICAL AUDITORY-EVOKED POTENTIALS AS A SURROGATE MARKER OF CENTRAL-NERVOUS-SYSTEM SEROTONIN TRANSMISSION IN MAN - DEMONSTRATION OF A CENTRAL EFFECT FOR THE 5HT(1B 1D) AGONIST ZOLMITRIPTAN (311C90, ZOMIG(R))/

      Cephalalgia
    75. DIXON RM; MEIRE HB; EVANS DH; WATT H; ON N; POSNER J; ROLAN PE
      PERIPHERAL VASCULAR EFFECTS AND PHARMACOKINETICS OF THE ANTIMIGRAINE COMPOUND, ZOLMITRIPTAN, IN COMBINATION WITH ORAL ERGOTAMINE IN HEALTHY-VOLUNTEERS

      Cephalalgia
    76. MARTIN GR
      PRECLINICAL PHARMACOLOGY OF ZOLMITRIPTAN (ZOMIG(TM), FORMERLY 311C90), A CENTRALLY AND PERIPHERALLY ACTING 5HT(1B) (1D) AGONIST FOR MIGRAINE/

      Cephalalgia
    77. DIXON R; WARRANDER A
      THE CLINICAL PHARMACOKINETICS OF ZOLMITRIPTAN

      Cephalalgia
    78. ROLAN P
      POTENTIAL-DRUG INTERACTIONS WITH THE NOVEL ANTIMIGRAINE COMPOUND ZOLMITRIPTAN (ZOMIG(TM), 311C90)

      Cephalalgia
    79. SCHOENEN J; SAWYER J
      ZOLMITRIPTAN (ZOMIG(TM), 311C90), A NOVEL DUAL CENTRAL AND PERIPHERAL5HT(1B 1D) AGONIST - AN OVERVIEW OF EFFICACY/

      Cephalalgia
    80. EDMEADS JG; MILLSON DS
      TOLERABILITY PROFILE OF ZOLMITRIPTAN (ZOMIG(TM), 311C90), A NOVEL DUAL CENTRAL AND PERIPHERALLY ACTING 5HT(1B 1D) AGONIST - INTERNATIONAL CLINICAL-EXPERIENCE BASED ON GREATER-THAN-3000 SUBJECTS TREATED WITH ZOLMITRIPTAN/

      Cephalalgia
    81. PECK RW; SEABER EJ; DIXON R; GILLOTIN CG; WEATHERLEY BC; LAYTON G; POSNER J
      THE INTERACTION BETWEEN PROPRANOLOL AND THE NOVEL ANTIMIGRAINE AGENT ZOLMITRIPTAN (311C90)

      British journal of clinical pharmacology
    82. SEABER E; ON N; DIXON RM; GIBBENS M; LEAVENS WJ; LIPTROT J; CHITTICK G; POSNER J; ROLAN PE; PECK RW
      THE ABSOLUTE BIOAVAILABILITY AND METABOLIC DISPOSITION OF THE NOVEL ANTIMIGRAINE COMPOUND ZOLMITRIPTAN (311C90)

      British journal of clinical pharmacology
    83. DIXON R; GILLOTIN C; GIBBENS M; POSNER J; PECK RW
      THE PHARMACOKINETICS AND EFFECTS ON BLOOD-PRESSURE OF MULTIPLE DOSES OF THE NOVEL ANTIMIGRAINE DRUG ZOLMITRIPTAN (311C90) IN HEALTHY-VOLUNTEERS

      British journal of clinical pharmacology
    84. SEABER EJ; RIDOUT G; LAYTON G; POSNER J; PECK RW
      THE NOVEL ANTIMIGRAINE COMPOUND ZOLMITRIPTAN (ZOMIG 311C90) HAS NO CLINICALLY SIGNIFICANT INTERACTIONS WITH PARACETAMOL OR METOCLOPRAMIDE

      European Journal of Clinical Pharmacology
    85. MARTIN GR; ROBERTSON AD; MACLENNAN SJ; PRENTICE DJ; BARRETT VJ; BUCKINGHAM J; HONEY AC; GILES H; MONCADA S
      RECEPTOR SPECIFICITY AND TRIGEMINO-VASCULAR INHIBITORY ACTIONS OF A NOVEL 5-HT1B 1D RECEPTOR PARTIAL AGONIST, 311C90 (ZOLMITRIPTAN)/

      British Journal of Pharmacology
    86. STORER RJ; GOADSBY PJ
      MICROIONTOPHORETIC APPLICATION OF SEROTONIN (5HT)(1B 1D) AGONISTS INHIBITS TRIGEMINAL CELL FIRING IN THE CAT/

      Brain
    87. GOADSBY PJ; HOSKIN KL
      INHIBITION OF TRIGEMINAL NEURONS BY INTRAVENOUS ADMINISTRATION OF THESEROTONIN (5HT)(1B D) RECEPTOR AGONIST ZOLMITRIPTAN (311C90) - ARE BRAIN-STEM SITES THERAPEUTIC TARGET IN MIGRAINE/

      Pain


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/10/20 alle ore 14:00:38